- Home
- DCTH vs ANL Comparison
DCTH vs ANL Comparison
Compare DCTH & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DCTH | ANL |
|---|---|---|
| Founded | 1988 | 2004 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.1M | 350.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DCTH | ANL |
|---|---|---|
| Price | $9.51 | $9.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $23.00 | $16.00 |
| AVG Volume (30 Days) | 487.7K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $132.21 | N/A |
| Revenue Next Year | $33.88 | N/A |
| P/E Ratio | $272.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.12 | $0.88 |
| 52 Week High | $18.23 | $12.09 |
Technical Indicators
Market Signals| Indicator | DCTH | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 45.36 | 76.51 |
| Support Level | $8.94 | $9.22 |
| Resistance Level | $10.30 | $10.15 |
| Average True Range (ATR) | 0.49 | 1.55 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 42.86 | 75.26 |
Price Performance
Historical ComparisonAbout DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.